Sign in Subscribe
COVID-19

mRNA Vaccines Associated with Increased Risk of Allergic Reactions

Strategic Insights

— 1 min read

New research from Istanbul University-Cerrahpasa has found that mRNA vaccines, particularly, have been associated with an increased risk of allergic reactions and rarely anaphylaxis. The study aimed to retrospectively evaluate the role of polyethylene glycol (PEG) sensitivity in vaccination decision-making in pediatric patients at high risk of allergy or with suspected allergic reactions to the first dose of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine.

Key Takeaways:

  • 17 patients enrolled in the study were found to have decreased readiness to receive the COVID-19 vaccine after developing hypersensitivity to multiple and/or injectable drugs.
  • 9 patients with negative tests received the vaccine without complications, while 4 patients recurred despite negative tests.
  • 3 patients with positive tests did not agree to desensitization with the mRNA vaccine, and 1 of them was vaccinated with the inactivated COVID-19 vaccine.
  • The study concluded that further research is needed on the hypersensitivity reactions of adjuvants, the predictive values of skin tests, and etiopathogenesis.
  • Researchers identified potential allergens such as PEG and polysorbate-80 used in COVID-19 vaccines.
  • The study involved 17 patients with suspected polyethylene glycol and polysorbate allergy before mRNA SARS-CoV2 vaccination.

Statistics:

  • 17 patients enrolled in the study
  • 9 patients received the vaccine without complications
  • 4 patients recurred despite negative tests
  • 3 patients with positive tests did not agree to desensitization with the mRNA vaccine
  • 1 patient was vaccinated with the inactivated COVID-19 vaccine
  • The study was published in Allergologia et Immunopathologia

Sources:

  • Evaluation of pediatric patients with suspected polyethylene glycol and polysorbate allergy before mRNA SARS-CoV2 vaccination. Allergologia et Immunopathologia, 2023;51(3):174-180.
  • Codon Publications, Level 9, 167 Eagle St, Brisbane, Qld 4000, Australia.
  • NewsRx LLC, Copyright 2023.

Read more